logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11697636 B1

PDFFull Text
Date of Patent:
Jul. 11, 2023

Filed:

Nov. 12, 2020

Substituted benzamides

Applicant:

Hoffmann-la Roche Inc., Nutley, NJ (US);

Inventors:

Katrin Groebke Zbinden, Liestal, CH;

Roger Norcross, Olsberg, CH;

Phillippe Pfileger, Schwoben, FR;

Assignee:

Hoffmann-La Roche Inc., Nutley, NJ (US);

Attorney:
Primary Examiner:

Sun Jae Yoo

Int. Cl.
CPC ...
C07D 207/09 (2006.01); C07D 207/10 (2006.01); C07D 207/12 (2006.01); C07D 211/26 (2006.01); C07D 241/04 (2006.01); C07D 263/32 (2006.01); C07D 265/30 (2006.01); C07D 267/08 (2006.01); C07D 267/10 (2006.01); C07D 295/135 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); A61K 9/20 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07D 207/09 (2013.01); A61K 9/2018 (2013.01); C07D 207/10 (2013.01); C07D 207/12 (2013.01); C07D 211/26 (2013.01); C07D 241/04 (2013.01); C07D 263/32 (2013.01); C07D 265/30 (2013.01); C07D 267/08 (2013.01); C07D 267/10 (2013.01); C07D 295/135 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 495/04 (2013.01);
Abstract

The invention relates to compounds of formula wherein R, R, R, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

Find Patent Forward Citations

Loading…